# GILEAD SCIENCES, INC.: Form 13F holdings

An institutional investment manager in FOSTER CITY, CA. SEC CIK 882095.

- Quarter ended: 2026-06-30
- Filed: 2026-08-03
- Reported value: $1.65bn
- Positions: 5 (5 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/882095/000112329226001034/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Arcus Biosciences Inc. (RCUS)](/companies/rcus.md) | COM | $968.8m | 58.8% | 31,424,760 |  | Unchanged |
| [Lakefront Biotherapeutics (LKFT)](/companies/lkft.md) | SPON ADR | $500.2m | 30.3% | 16,707,477 |  | Unchanged |
| [Assembly Biosciences Inc. (ASMB)](/companies/asmb.md) | COM NEW | $136.8m | 8.3% | 4,977,089 |  | Added +471,698 |
| [Kyverna Therapeutics Inc. (KYTX)](/companies/kytx.md) | COM | $36.8m | 2.2% | 4,126,119 |  | Unchanged |
| Xilio Therapeutics Inc. | COM | $6.2m | 0.4% | 650,389 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| Arcellx Inc | COM | $0 | 0.0% | 0 |  | Sold out −6,720,803 |

Source: SEC EDGAR, Form 13F-HR, accession 0001123292-26-001034. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.